
Trump's upcoming measures aim to boost psychedelic research, signaling a shift in drug policy that could reshape mental health treatment in America.
2026-04-18Trump's executive order aims to expedite the review of psychedelics like ibogaine for treating depression and addiction, signaling a shift in drug policy.
2026-04-18
Trump's executive order aims to expedite ibogaine access, signaling a shift in US drug policy and mental health treatment.
2026-04-18
Trump's order to expedite psychedelic drug reviews marks a conservative shift in drug policy, focusing on treatment for addiction and PTSD.
2026-04-18
Trump's executive order aims to expedite psychedelic drug reviews, focusing on ibogaine for veterans' PTSD and addiction treatment.
2026-04-18